Levodopa/carbidopa Intestinal Gel in Treatment of Non-Motor Symptoms in Advanced Parkinson’s Disease
Objective: To identify the advantages of LCIG in the treatment of NMS among APD patients and appraise the currently available literature to identify the gaps…Postural and kinetic tremor is associated with pallidal dopamine denervation in patients with Parkinson’s disease
Objective: To investigate the role of dopamine denervation in the globus pallidus in PD patients with postural and kinetic tremor (PT/KT) in Parkinson’s disease(PD) using…Role of clinical neuroimaging in X-linked dystonia-parkinsonism
Objective: To determine the inter- and intra-rater reliability of brain imaging in X-linked dystonia-parkinsonism (XDP). Background: XDP is a neurodegenerative movement disorder presenting with adult-onset…FDG PET: a good predictive tool for CNS inflammation
Objective: 1)When to suspect an underlying autoimmune process in patients presenting with parkinsonism. 2)To highlight the importance of FDG PET as a complementary exam in…Appropriateness of DAT Scan Ordering in a University Hospital Practice
Objective: To examine the diagnostic utility (or misuse) of DAT scanning in a University Hospital practice – is there unnecessary utilisation of DAT scanning when…Kick Out PD: Mobility, Quality of Life, and Feasibility Outcomes in a Pilot Study of a PD-Specific Karate Intervention
Objective: To evaluate feasibility of a community-based karate class tailored for individuals with early- to middle-stage Parkinson’s Disease (PD); to assess effect of karate on…Predicting the efficacy of STN-DBS in patients with different Parkinson’s disease motor subtypes by preoperative total and partial levodopa response
Objective: To better investigate the value of the challenge test by introducing total and partial LR, and explain the clinical significance of 30% LR through…Lack of Notable Skin Reactions from a Novel Levodopa/Carbidopa Prodrug after 10 Days of Repeated 24-Hour Continuous Subcutaneous Infusion at the Same Administration Site
Objective: To assess the skin safety and tolerability of 24-hour continuous subcutaneous infusion (CSCI) of ABBV-951. Background: Therapeutic approaches for advanced Parkinson’s disease (aPD) patients…OPICAPONE: REAL WORLD EVIDENCE IN TOLEDO´S MOVEMENT DISORDERS UNIT
Objective: We present a prospective observational-real life study about the use in Movement Disorders Unit´s patients, since its commercialization in Spain (June 2017). Background: The…Vortioxetine treatment of depression in Parkinson’s disease
Objective: To assess efficacy and safety of Vortioxetine in Parkinson’s Disease (PD) patients affected by depression and its effects on motor performance. Background: Depression is…
- « Previous Page
- 1
- …
- 159
- 160
- 161
- 162
- 163
- …
- 388
- Next Page »